利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

78 条记录 (耗时 0.021 秒)

    Novel Pharmaceutical Modified Release Dosage Form Cyclooxygenase Enzyme Inhibitor
    2.
    发明申请
    Novel Pharmaceutical Modified Release Dosage Form Cyclooxygenase Enzyme Inhibitor 审中-公开
    新型药物改性释放剂型环氧合酶抑制剂

    公开(公告)号：US20100204333A1

    公开(公告)日：2010-08-12

    申请号：US11988860

    申请日：2006-07-19

    申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh ,  Munish Talwar

    发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh ,  Munish Talwar

    IPC分类号： A61K31/18 ,  A61P25/00 ,  A61P25/06

    CPC分类号： A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/209 ,  A61K9/4808 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/5084 ,  A61K31/18 ,  A61K31/192 ,  A61K31/415

    摘要： Pharmaceutical modified release dosage form comprising at least one cyclooxygenase enzyme inhibitor or its pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof as active agent, with a pharmaceutically acceptable carrier for controlling the release of the cyclooxygenase enzyme inhibitor is provided. The dosage form preferably provides a release of not more than about 60% of the cyclooxygenase enzyme inhibitor in 1 hour and not less than about 75% of the cyclooxygenase enzyme inhibitor after 12 hours when tested in accordance with the dissolution method (I) described herein employing Distilled water with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (II) described herein employing pH 7.0 Phosphate buffer with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (III) described herein employing 0.001 N Hydrochloric acid with 1.0% Sodium lauryl sulphate as dissolution medium. Further, the pharmaceutical composition of the present invention when tested in a group of healthy humans preferably achieves a mean peak plasma concentration (Cmax) after at least about 1 hour of administration of the dosage form. The present invention also provides process of preparing such dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form.

    摘要翻译： 提供了包含至少一种环加氧酶酶抑制剂或其药学上可接受的盐，酯，前药，溶剂化物或其衍生物作为活性剂的药物改性释放剂型，以及用于控制环加氧酶抑制剂释放的药学上可接受的载体。 根据本文所述的溶解方法（I）测试时，剂型优选在12小时后提供不超过约60％的环氧合酶抑制剂的释放量，并且不少于约75％的环氧合酶抑制剂。 使用2.0％十二烷基硫酸钠作为溶解介质的蒸馏水或根据本文所述的溶解方法（II），使用pH 7.0的磷酸盐缓冲液，含有2.0％十二烷基硫酸钠作为溶解介质，或根据溶解方法（III） 本文使用0.001N盐酸与1.0％十二烷基硫酸钠作为溶解介质。 此外，当在一组健康人中测试时，本发明的药物组合物优选在施用剂型至少约1小时后达到平均峰值血浆浓度（C max）。 本发明还提供了制备这种剂型组合物的方法和使用这种剂型的预防和/或治疗方法。

    NOVEL LOW DOSE PHARMACEUTICAL COMPOSITIONS COMPRISING NIMESULIDE, PREPARATION AND USE THEREOF
    3.
    发明申请
    NOVEL LOW DOSE PHARMACEUTICAL COMPOSITIONS COMPRISING NIMESULIDE, PREPARATION AND USE THEREOF 审中-公开
    包含NIMESULIDE的新型低剂量药物组合物，其制备和使用

    公开(公告)号：US20090258947A1

    公开(公告)日：2009-10-15

    申请号：US12298054

    申请日：2007-04-23

    申请人： Rajesh Jain ,  Kour Chand Jindal

    发明人： Rajesh Jain ,  Kour Chand Jindal

    IPC分类号： A61K31/16 ,  A61P25/00

    CPC分类号： A61K31/18 ,  A61K9/0019 ,  A61K9/0095 ,  A61K9/2018 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/485 ,  A61K9/4858

    摘要： Low dose pharmaceutical dosage form comprising nimesulide or its pharmaceutically acceptable salts, esters, solvates or hydrates thereof, along with one or more pharmaceutically acceptable excipient(s) are provided. The present invention also provides process of preparing such dosage forms and therapeutic methods of using such dosage forms. The low dose compositions 10 are designed to exhibit such bioavailability, which is effective in the treatment of NSAID indicated disorders particularly, which require long-term treatment regimens such as arthritis. Such compositions reduce the cost of therapy in diseases, which require long-term therapies, are easy to manufacture, and also result in the reduction of dose related side effects associated with nimesulide therapy.

    摘要翻译： 提供了包含尼美舒利或其药学上可接受的盐，酯，溶剂化物或其水合物以及一种或多种药学上可接受的赋形剂的低剂量药物剂型。 本发明还提供了制备这种剂型的方法和使用这种剂型的治疗方法。 低剂量组合物10被设计为表现出这样的生物利用度，其在治疗特别是需要长期治疗方案例如关节炎的NSAID指征的病症中是有效的。 这样的组合物降低了需要长期疗法，易于制备的疾病的治疗成本，并且还导致与尼美舒利治疗相关的剂量相关的副作用的减少。

    INJECTABLE DEPOT COMPOSITIONS AND ITS PROCESS OF PREPARATION
    4.
    发明申请
    INJECTABLE DEPOT COMPOSITIONS AND ITS PROCESS OF PREPARATION 审中-公开
    可注射成分组合物及其制备方法

    公开(公告)号：US20100098735A1

    公开(公告)日：2010-04-22

    申请号：US12444257

    申请日：2007-10-03

    申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sampath Kumar Devarajan

    发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sampath Kumar Devarajan

    IPC分类号： A61K9/00 ,  A61K31/4196 ,  A61K31/18 ,  A61K9/14 ,  A61P35/00

    CPC分类号： A61K9/0024 ,  A61K9/06 ,  A61K9/1647

    摘要： Novel injectable compositions are provided comprising an active agent which is tamsulosin or letrozole or its pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof and one or more pharmaceutically acceptable excipient(s) wherein the compositions are preferably formulated as biodegradable microparticles or nanoparticles which can optionally be reconstituted with an aqueous, hydro-alcoholic or oily liquid vehicle prior to administration. The novel injectable compositions of the present invention preferably form a depot upon administration in vivo and are in the form of an in situ gelling composition or an implant composition which provides a prolonged release of tamsulosin or letrozole for extended periods of time. Also described are process for preparation of such novel compositions and method of using them.

    摘要翻译： 提供新的可注射组合物，其包含活性剂，其为坦索罗辛或来曲唑或其药学上可接受的盐，衍生物，异构体，多晶型物，溶剂合物，水合物，类似物，对映体，互变异构形式或其混合物，以及一种或多种药学上可接受的赋形剂，其中 组合物优选配制成可生物降解的微粒或纳米颗粒，其可以在施用前任选地用水性，水性醇或油性液体载体重构。 本发明的新型可注射组合物优选在体内施用时形成贮库，并且是呈现长时间释放坦索罗辛或来曲唑的原位胶凝组合物或植入物组合物的形式。 还描述了这种新型组合物的制备方法和使用它们的方法。

    INJECTABLE DEPOT COMPOSITIONS AND IT'S PROCESS OF PREPARATION
    5.
    发明申请
    INJECTABLE DEPOT COMPOSITIONS AND IT'S PROCESS OF PREPARATION 审中-公开
    注射剂组合物及其制备方法

    公开(公告)号：US20100015195A1

    公开(公告)日：2010-01-21

    申请号：US12444197

    申请日：2007-10-03

    申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sampath Kumar Devarajan

    发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sampath Kumar Devarajan

    IPC分类号： A61K31/496 ,  A61K31/4196 ,  A61K31/445 ,  A61K31/498 ,  A61K9/00 ,  A61K9/14 ,  A61P35/00

    CPC分类号： A61K9/0024 ,  A61K9/06 ,  A61K9/1647

    摘要： Novel injectable depot compositions are provided comprising at least one active agent(s) optionally with one or more pharmaceutically acceptable excipient(s) in the form of a multi-component system preferably comprising at least two components which when administered to a subject in need thereof forms an in situ gel depot or implant at the site of injection upon contact with body fluids. Also described are process for preparation of such compositions and method of using such compositions.

    摘要翻译： 提供了新的可注射贮库组合物，其包含至少一种活性剂，其任选地具有多组分体系形式的一种或多种药学上可接受的赋形剂，优选包含至少两种组分，当其施用于有需要的受试者时 在与体液接触时在注射部位形成原位凝胶储库或植入物。 还描述了制备这种组合物的方法和使用这种组合物的方法。

    Pharmaceutical compositions comprising an extract of Euphorbia prostrata
    6.
    发明授权
    Pharmaceutical compositions comprising an extract of Euphorbia prostrata 有权
    包含大戟提取物的药物组合物

    公开(公告)号：US07371412B2

    公开(公告)日：2008-05-13

    申请号：US10551797

    申请日：2004-12-31

    申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh ,  Aniruddha Datta

    发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh ,  Aniruddha Datta

    IPC分类号： A61K36/00

    CPC分类号： A61K36/47 ,  A61K36/185 ,  A61K36/48 ,  A61K2300/00

    摘要： The invention relates to novel compositions comprising of an extract of the plant Euphorbia prostrata, particularly with pharmaceutically acceptable carrier(s)/base(s), optionally with additional therapeutic agent(s) useful for the treatment of anorectal disease and colonic diseases such as hemorrhoids, fissures, cracks, fistulas, abscesses, inflammatory bowel disease, and the like. The novel compositions possess properties to control inflammation, prevent capillary bleeding and fragility in mammalians, particularly human beings. Process for the preparation of such novel compositions comprising an extract of the plant Euphorbia prostrata and pharmaceutically acceptable carrier(s)/base(s) useful for the treatment of anorectal disease including hemorrhoids, and colonic diseases are also provided. The composition comprise of flavonoidal and phenolic constituents extracted from the plant Euphorbia prostrata that possess anti-inflammatory, analgesic, haemostatic and wound-healing properties.

    摘要翻译： 本发明涉及包含植物大戟提取物，特别是与药学上可接受的载体/碱的提取物的新型组合物，任选地可用于治疗肛门直肠疾病和结肠疾病的其它治疗剂，例如 痔疮，裂缝，裂缝，瘘，脓肿，炎症性肠病等。 该新型组合物具有控制哺乳动物，特别是人类的炎症，防止毛细血管出血和脆性的性质。 还提供了制备这种新型组合物的方法，该组合物包含植物大戟草提取物和可用于治疗包括痔疮和结肠疾病在内的肛门直肠疾病的药学上可接受的载体/碱基。 该组合物包含从具有抗炎，镇痛，止血和伤口愈合特性的植物大戟科提取的黄酮和酚成分。

    Composition comprising at least one higher aliphatic alcohol and an extract of Griffonia simplicifolia
    7.
    发明授权
    Composition comprising at least one higher aliphatic alcohol and an extract of Griffonia simplicifolia 失效
    组合物，其包含至少一种高级脂肪醇和甘草提取物

    公开(公告)号：US07956067B2

    公开(公告)日：2011-06-07

    申请号：US12299317

    申请日：2007-05-09

    申请人： Rajesh Jain ,  Kour Chand Jindal

    发明人： Rajesh Jain ,  Kour Chand Jindal

    IPC分类号： A61K31/44 ,  A61K31/40 ,  A61K36/00 ,  A61K36/82

    CPC分类号： A61K36/48 ,  A61K31/045 ,  A61K36/82 ,  A61K2300/00

    摘要： Novel compositions comprising a combination of at least one higher primary aliphatic alcohol preferably selected from those having 18 to 40 carbon atoms or mixtures thereof, at least one source of 5-hydroxytryptophan (5-HTP) optionally additionally comprising a source of caffeine and/or catechin-polyphenol and/or epigallocatechin gallate as active agents, either alone or in combination with other active agent(s), optionally with one or more excipient(s) are provided. Particularly, the invention relates to compositions and process for preparation of such compositions and method of use thereof for the management of obesity and associated disorders.

    摘要翻译： 包含至少一种优选选自具有18-40个碳原子的高级伯脂肪醇或其混合物的至少一种5-羟基色氨酸（5-HTP）的组合的新型组合物任选地另外包含咖啡因和/或 儿茶素多酚和/或表没食子儿茶素没食子酸酯作为活性剂，单独或与其它活性剂，任选地与一种或多种赋形剂组合使用。 特别地，本发明涉及用于制备这种组合物的组合物和方法及其用于治疗肥胖症和相关疾病的方法。

    Compositions Comprising Glycosaminoglycan and Nonsteroidal Anti-Inflammatory Drug
    10.
    发明申请
    Compositions Comprising Glycosaminoglycan and Nonsteroidal Anti-Inflammatory Drug 审中-公开
    包含糖胺聚糖和非甾体抗炎药的组合物

    公开(公告)号：US20080261866A1

    公开(公告)日：2008-10-23

    申请号：US10586544

    申请日：2005-01-19

    申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh

    发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh

    IPC分类号： A61K38/00 ,  A61K31/715 ,  A61P1/00

    CPC分类号： A61K31/726 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2866 ,  A61K9/4866 ,  A61K31/18 ,  A61K31/196 ,  A61K31/405 ,  A61K31/727 ,  A61K31/728 ,  A61K2300/00

    摘要： Pharmaceutical compositions comprising of glycosaminoglycan or salts thereof, preferably chondroitin or salts thereof, more preferably chondroitin sulphate, and nonsteroidal anti-inflammatory drug(s) or salts thereof, optionally with pharmaceutically acceptable excipient(s) are described. The compositions of the present invention provide gastrosparing effect in conditions where nonsteroidal anti-inflammatory drug(s) or their salts are used, particularly in mammals. Also provided are process for the manufacture of such novel compositions and method to minimize the nonsteroidal anti-inflammatory drug(s) induced gastric toxicity.

    摘要翻译： 描述了包含糖胺聚糖或其盐的药物组合物，优选软骨素或其盐，更优选硫酸软骨素，以及任选具有药学上可接受的赋形剂的非甾体抗炎药或其盐。 本发明的组合物在使用非甾族抗炎药或其盐的条件下，特别是在哺乳动物中提供胃镜效应。 还提供了制备这种新型组合物和方法以使非甾体抗炎药物诱导的胃毒性最小化的方法。